Zheng Shusen

Zheng Shusen

He was born in January 1950, professor and director of Department of liver transplantation, National Academy of health of Zhejiang Province.

After graduating from the Department of clinical medicine of Zhejiang Medical University in 1973, Zheng Shusen stayed in the university to teach; obtained a master's degree from Zhejiang Medical University in 1986; was elected academician of the Chinese Academy of Engineering in 2001; and was elected foreign academician of the French National Academy of Medical Sciences in 2017.

Zheng Shusen, who is engaged in organ transplantation and hepatobiliary and pancreatic surgery, first proposed the "Hangzhou standard" for the selection of liver transplant recipients and a new scheme for the prevention and treatment of hepatitis B recurrence after liver transplantation.

Character experience

After graduating from the Department of clinical medicine of Zhejiang Medical University in 1973, Zheng Shusen stayed to teach. In 1986, Zheng Shusen graduated from Zhejiang Medical University with a master's degree. in 1989, he graduated from West China Medical University with a doctor's degree. In 2001, Zheng Shusen was elected academician of the Chinese Academy of engineering. In 2009, as a Chinese expert, Zheng Shusen participated in the formulation of the world gastroenterology organization's global guidelines for the diagnosis and treatment of liver cancer. in 2017, Zheng Shusen was elected a foreign academician of the French National Academy of Medical Sciences.

Main achievements

Achievements in scientific research

For the first time in the world, Zheng Shusen put forward the selection criteria of liver transplantation recipients for liver cancer including biological characteristics of tumor - "Hangzhou standard", established the technical system of adult living donor liver transplantation and low-dose hepatitis B immunoglobulin (HBIG) combined with nucleoside analogues to prevent hepatitis B recurrence after liver transplantation.

Joint multiple organ transplantation

in the early 1990s, he went to Mary Hospital, Department of surgery, University of Hong Kong to do postdoctoral research. In October 1991, as the first assistant, he participated in the first human orthotopic liver transplantation in Hong Kong, which was listed as one of the top ten news in Hong Kong. Since the first liver transplantation in Zhejiang Province was carried out in 1993, more than 860 cases of liver transplantation have been performed, including more than 150 cases of living donor liver transplantation. The 1-year survival rate of patients with benign liver disease is 95.2%, reaching the international advanced level. In 2001, a 9-month-old child with congenital biliary atresia received living donor liver transplantation from his mother, which was the youngest record in China at that time. In 2001, the first adult living donor liver transplantation was performed in China. In 2007, 1 Chinese mainland children with congenital biliary atresia who were born only 106 days underwent liver transplantation. the joint multiple organ transplantation project led by Zheng Shusen was listed as a promotion project by the Ministry of health. Since the simultaneous pancreas kidney transplantation and liver kidney transplantation were carried out in 1994 and 1999 respectively, the number of cases is the largest and the effect of transplantation is the best. The recipients of simultaneous pancreas kidney transplantation have created and maintained the longest survival record in Asia (16 years), and the recipients of combined liver kidney transplantation have created and maintained the longest survival record in China (11 years). Zheng Shusen has helped Peking Union Medical College Hospital, Huashan Hospital of Fudan University, Shanghai Xinhua Hospital, the First Affiliated Hospital of Xinjiang Medical University and other hospitals to carry out liver transplantation. His technology has spread to more than 20 provinces and cities in China, and vigorously promoted the healthy development of organ transplantation in China. over the past 20 years, he has been committed to innovating surgical concepts and technologies to promote the development of organ transplantation in China. In China, we took the lead in carrying out a number of innovations, such as non venous venous bypass, microsurgical anastomosis of biliary tract and blood vessel, and living donor liver transplantation technology innovation. We took the lead in applying artificial liver support system and liver transplantation in the treatment of advanced severe hepatitis, and took the lead in establishing a new technical specification for perioperative management of liver transplantation. Our new strategy for prevention and treatment of hepatitis B recurrence after liver transplantation in the world has been recognized by the international academic community Yes.

The Hangzhou standard of liver transplantation with great international influence was put forward

in 2006, Zheng Shusen established the "Hangzhou standard" for the first time in the world, which is suitable for the selection of liver transplantation recipients for liver cancer in China: (1) no portal vein tumor thrombus; (2) the cumulative diameter of tumor is less than or equal to 8cm or more, the preoperative AFP is less than or equal to 400ng / ml, and the histological grade is high / medium differentiation. The project won the second prize of national science and technology progress award. The proposal of "Hangzhou standard" has increased the chance of liver cancer transplantation by 37%, which has given more patients with liver cancer who could not be operated with a chance of survival. The International Transplantation academic circles highly praise this. Professor bustell, President of the American Association of transplant surgeons, wrote that "Hangzhou standard" is superior to other standards and is a great contribution to the field of transplantation. The Chinese standard of liver transplantation for hepatocellular carcinoma was published for the first time in the top journal of transplantation. in December 2016, academician Zheng Shusen of Zhejiang University was selected as the "top ten scientific and technological progress of Chinese universities" in 2016 based on the project of "Research on new molecular hierarchical system of liver transplantation for liver cancer". as of December 2017, Zheng Shusen's team has successfully implemented liver transplantation in more than 2300 cases, with a 1-year survival rate of 95.2% in patients with benign liver diseases, and a 5-year survival rate of 72.5% in patients with liver cancer who met the "Hangzhou standard" for liver transplantation for liver cancer proposed by Zheng Shusen in 2006, creating a precedent for domestic emergency living donor liver transplantation in the treatment of acute liver failure. as the corresponding author, Zheng Shusen has published more than 200 papers in such SCI journals as gut, Journal of Pathology, livertransplantation, and transplantation. Zheng Shusen edited the International Journal of hepatobiliary and pancreatic diseases (hbpdint, SCI), Chinese Journal of transplantation (Electronic Edition), liver transplantation, pancreas transplantation and other monographs. as the chief scientist, Zheng Shusen presided over two national key basic research and development programs (973 Program) in the field of organ transplantation in China. Zheng Shusen successively won one first prize and two second prizes of national science and technology progress award.

personnel training

Zheng Shusen, chief editor of the Ministry of education, planned the textbook surgery for five years and eight years. the organ transplantation research team led by Zheng Shusen won the "Yangtze River scholar and innovation team development plan" of the Ministry of education in 2007. Zheng Shusen has trained 6 postdoctors and more than 160 postgraduates.

Honorary recognition

Social service

Zheng Shusen served as vice president of Chinese Medical Association; vice chairman of surgery branch of Chinese Medical Association and head of organ transplantation group; chairman of organ transplantation branch of Chinese Medical Association; chairman of clinical medicine teaching steering committee of Ministry of education; member of second Department of life science department of Ministry of education; chairman of Zhejiang surgical society; chairman of Zhejiang organ transplantation society Member of the Chinese Academy of surgery; deputy head of the Chinese society of surgery; head of liver transplantation; head of organ transplantation; member of American Surgical Association (FACS); International Committee of liver transplantation (ILTS); member of the Chinese mainland; member of the international hepatobiliary and pancreatic Association; International Committee on liver diseases; International Journal of hepatobiliary and pancreatic diseases and Chinese Journal of transplantation. He is the chief editor of Chinese Journal of surgery, Chinese Journal of organ transplantation, Chinese Journal of general surgery, Chinese Journal of Practical Surgery, Chinese Journal of basic and clinical general surgery and other academic journals.

Character evaluation

Zheng Shusen is a famous scientist and medical educator of hepatobiliary and pancreatic surgery in China, and a pioneer and academic leader of organ transplantation and multiple organ transplantation in China. (review of the First Affiliated Hospital of Zhejiang University) Baidu Encyclopedia content is shared by netizens. If you find that your data content is inaccurate or incomplete, you are welcome to use my data service (free) to participate in the correction. Go to > > now

Chinese PinYin : Zheng Shu Sen